FDA approve 600mg darunavir tablet
1 April 2008. Related: Antiretrovirals.
Antiretrovirals
US study changes use of abacavir/3TC in naive patients with viral load >100,000 copies based on DSMB recommendation
1 April 2008. Related: Antiretrovirals.
Boehringer fails to register tipranavir in Brazil after using Brazilian patients in registrational study
1 February 2008. Related: Antiretrovirals, Treatment access.
Raltegravir approved in Europe and available in the UK
1 February 2008. Related: Antiretrovirals.
Paediatric lopinavir/r receives positive opinion from EMEA
1 February 2008. Related: Antiretrovirals.
Etravirine (TMC-125) approved in the US
1 February 2008. Related: Antiretrovirals.
Changes to atazanavir product label in US
1 February 2008. Related: Antiretrovirals.
HIV-positive adults with CD4 >500 cells/mm3 have similar mortality rates as the general population after seven years ARV treatment
1 February 2008. Related: Antiretrovirals.
Saquinavir/r non-inferior to Kaletra at week 48 (Gemini study)
2 December 2007. Related: Conference reports, Antiretrovirals.
Darunavir once-daily is non-inferior to lopinavir/r in treatment-naive patients at 48 weeks (Artemis study)
2 December 2007. Related: Conference reports, Antiretrovirals.
Half-dose Kaletra tablet approved for paediatric use in the US
1 December 2007. Related: Antiretrovirals, Paediatric care.
Atripla approved in Europe as switch option for suppressed patients
2 October 2007. Related: Antiretrovirals.
Maraviroc approved in Europe for treatment-experienced CCR5-tropic patients
2 October 2007. Related: Antiretrovirals.
Paediatric formulation of fosamprenavir approved in Europe
2 October 2007. Related: Antiretrovirals.
Raltegravir approved in the US
2 October 2007. Related: Antiretrovirals.
EMEA recommends reinstating license for Roches nelfinavir
2 October 2007. Related: Antiretrovirals.
Roche withdraw application for Biojector needle-free option for T-20
2 October 2007. Related: Antiretrovirals.
Darunavir/r shows superiority over lopinavir/r at 48 weeks in TITAN trial
3 September 2007. Related: Conference reports, Antiretrovirals.
Maraviroc fails to show non-inferiority to efavirenz in treatment-naive patients: 48 week results
3 September 2007. Related: Conference reports, Antiretrovirals.
Importance of using maraviroc in combination with other active drugs in treatment-experienced patients
3 September 2007. Related: Conference reports, Antiretrovirals.
Week 48 raltegravir results in treatment-naive phase II dose-finding study
3 September 2007. Related: Conference reports, Antiretrovirals.
DUET studies clarify antiviral efficacy of etravirine and cross-resistance profile to other NNRTIs
3 September 2007. Related: Conference reports, Antiretrovirals.
Boosting atazanavir in treatment-naive patients, and impact on lipids after switching from lopinavir/r
3 September 2007. Related: Conference reports, Antiretrovirals.
Saquinavir/r vs lopinavir/r in treatment-naive patients
3 September 2007. Related: Conference reports, Antiretrovirals.
Fosamprenavir/r vs atazanvir/r in treatment-naive patients
3 September 2007. Related: Conference reports, Antiretrovirals.
Maraviroc approved in the US
3 September 2007. Related: Antiretrovirals.
Monogram launches Trofile HIV co-receptor tropism test
3 September 2007. Related: Antiretrovirals.
Raltegravir (MK-0518) phase 3 trials show successful viral suppression in multi-drug resistant patients
4 April 2007. Related: Conference reports, Antiretrovirals, Drug resistance.
Maraviroc phase 2b/3 results in treatment experienced CCR5-tropic patients
4 April 2007. Related: Conference reports, Antiretrovirals.
Phase 2 study of Gileads integrase inhibitor elvitegravir (GS-9137)
4 April 2007. Related: Conference reports, Antiretrovirals.
Phase 2b study comparing rilpivirine (TMC-278) to efavirenz in treatment-naive patients: 48-week results
4 April 2007. Related: Conference reports, Antiretrovirals.
PK results from heat-stable formulation of ritonavir
4 April 2007. Related: Conference reports, Antiretrovirals.
Use of low-dose rapamycin, a CCR5 suppressant, to increase potency of T-20 in vitro
4 April 2007. Related: Conference reports, Antiretrovirals.
Darunavir (TMC-114) approved in Europe
4 April 2007. Related: Antiretrovirals.
No significant interaction reported between etravirine (TMC125) and raltegravir (MK-0518)
4 April 2007. Related: Antiretrovirals.
Future of second-generation fusion inhibitors less certain as Trimeris and Roche separate
4 April 2007. Related: Antiretrovirals.
Pharmacokinetic study of Triomune-40 in Malawi: higher d4T exposure suggests importance of using lower dose formulations of d4T
5 February 2007. Related: Antiretrovirals.
GSK stops development of brecanavir
5 February 2007. Related: Antiretrovirals.
FDA analysis of predicted responses to tipranavir/r
5 February 2007. Related: Antiretrovirals.
Important changes to US prescribing information for efavirenz
5 February 2007. Related: Antiretrovirals.
Changes to US product label for T-20 (enfuvirtide)
5 February 2007. Related: Antiretrovirals.
Explanation for failure of TMC-125 (etravirine) in TMC227 study
6 December 2006. Related: Conference reports, Antiretrovirals.
Saquinavir/r vs lopinavir/r: interim results from the Gemini study
6 December 2006. Related: Conference reports, Antiretrovirals.
TMC 114 recommended for conditional approval in Europe
6 December 2006. Related: Antiretrovirals.
Atazanavir 300mg capsule approved in US
6 December 2006. Related: Antiretrovirals.
Lipid profile of integrase inhibitor MK-0518: 24 week results compared to efavirenz in treatment naive patients
7 October 2006. Related: Conference reports, Antiretrovirals.
NRTI elvucitabine active against HIV in a 7-day monotherapy study
7 October 2006. Related: Conference reports, Antiretrovirals.
Efavirenz/tenofovir fails as 2-drug maintenance regimen
7 October 2006. Related: Conference reports, Antiretrovirals.
Early access programme for MK-0518 integrase inhibitor
7 October 2006. Related: Antiretrovirals.
Etravirine (TMC-125) available on named patient programme in the UK
7 October 2006. Related: Antiretrovirals.
Fixed dose combination (FDC) of tenofovir/FTC/efavirenz (Atripla) filed in EU
7 October 2006. Related: Antiretrovirals.
Tipranavir available in Scotland – almost one year after EU approval
7 October 2006. Related: Antiretrovirals.
FDA decision delayed on Biojector for administering T-20 pending additional safety information
7 October 2006. Related: Antiretrovirals.
Integrase inhibitor MK-0518: early results show greater early potency than efavirenz
10 September 2006. Related: Conference reports, Antiretrovirals.
Maraviroc results in R5/X4 mixed/dual tropic patients: unexpected safety data shows possible immunolocical effect
10 September 2006. Related: Conference reports, Antiretrovirals.
Vicriviroc 24-week results in triple-class experienced R5-tropic patients
10 September 2006. Related: Conference reports, Antiretrovirals.
Etravirine (TMC-125) associated with -1 log viral load reduction at 48-weeks results in treatment experienced patients
9 September 2006. Related: Conference reports, Antiretrovirals.
Three-class experienced patients experience 1 log viral load reduction using monoclonal antibody TNX-355
9 September 2006. Related: Conference reports, Antiretrovirals.
New data on darunavir (TMC-114)
9 September 2006. Related: Conference reports, Antiretrovirals.
Lopinavir/r monotherapy: less potent than triple therapy with higher risk of resistance
9 September 2006. Related: Conference reports, Antiretrovirals.
Atazanavir/r monotherapy and CNS penetration
9 September 2006. Related: Conference reports, Antiretrovirals.
Fosamprenavir/r is non-inferior to Kaletra in treatment naive patients
9 September 2006. Related: Conference reports, Antiretrovirals.
Tenofovir/FTC maintains greater virological response and reduced lipoatrophy compared to AZT/3TC after 96 weeks
9 September 2006. Related: Conference reports, Antiretrovirals.
Antiretroviral effect of foscarnet in patients with multiple drug resistance in late stage HIV disease
9 September 2006. Related: Antiretrovirals.
New formulation of lopinavir/r approved in Europe (Kaletra) and new tradename for access countries (Aluvia)
3 August 2006. Related: Antiretrovirals.